Upfront autologous stem cell transplantation for newly diagnosed multiple myeloma

Bookmark and Share
Published: 6 Jun 2016
Views: 1299
Prof Michele Cavo - Seràgnoli Institute of Hematology, Bologna, Italy

Dr Cavo meets with ecancertv at ASCO 2016 to discuss the role of autologous stem cell transplantation (ACST) for multiple myeloma (MM).

With the changing landscape of novel agents, the role of upfront transplantation has been questioned, and was put to the test in a randomized phase III trial comparing 4 cycles of bortezomib-melphalan-prednisone (VMP) against high-dose melphalan (HDM) and single or double ASCT as intensification therapy following induction with bortezomib-cyclophosphamide-dexamethasone and subsequent collection of peripheral blood stem cells.

Progression free survival and partial response rates favour the inclusion of ACST as the preferred treatment for younger, newly diagnosed MM patients, with overall survival data yet to mature.